Physician profile
Suneel B Bhat
NPI 1578854956
$181,558.10
in general payments reported to CMS, 2019-2025
6 companies · $12K in 2025
The $12K reported for 2025 was more than what 80% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $4,750 · 2021: $8,877 · 2022: $17K · 2023: $127K · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $104K · Consulting Fee: $45K · Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $104,189.47 |
| Consulting Fee | $45,250.00 |
| Food and Beverage | $1,626.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $104,189.47 | 2023-2025 | Tapestry |
| Stryker Corporation | $72,075.84 | 2021-2025 | T2 Alpha, Axsos, Pangea |
| Embody, INC. | $4,750.00 | 2020 | |
| Depuy Synthes Sales INC. | $297.76 | 2021-2025 | Na, Va-Lcp |
| Amgen INC. | $245.03 | 2025 | Prolia, Evenity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$378,378.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneel Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.